Evidence map›Paper›PMID 39268677›Full record

ArticleImmunotherapy2024

Bioengineering MSCs for untapped therapeutic potential.

Olivia Sirpilla, Saad S Kenderian

Abstract readEditorial
In one paragraph

Article in Immunotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Mesenchymal stromal cell therapy: Progress to date and future outlook.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Olivia SirpillaT Cell Engineering, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-0634-407X
Saad S KenderianT Cell Engineering, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-2767-3830

Funding

Paul Calabresi Program in Clinical/Translational Research at Mayo ClinicK12CA090628 · NCI · MAYO CLINIC ROCHESTER · PI WEROHA, SARAVUT · 2001 to 2025
$19.7M
Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid CytokinesR37CA266344 · NCI · MAYO CLINIC ROCHESTER · PI Saad J. Kenderian · 2022 to 2026
$3.5M
Engineered Mesenchymal Stromal Cells for Enhanced ImmunosuppressionR01AI179974 · NIAID · MAYO CLINIC ROCHESTER · PI Saad J. Kenderian · 2024 to 2026
$2.4M
Simultaneous Thermal and Osmotic Stresses in Tumor Ablation: Imaging and BiologyR01CA201127 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CRESSMAN, ERIK N · 2016 to 2020
$2.3M
NCI NIH HHS K12 CA090628NCI NIH HHS R01 CA201127NCI NIH HHS R37 CA266344NIAID NIH HHS R01 AI179974NIHMS R37CA266344, R01AI179974
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BioengineeringMesenchymal Stem CellsAnimalsHumansMesenchymal Stem Cell TransplantationTissue EngineeringbioengineeringCARcell therapyimmunosuppressionMSC

Identifiers

PMID39268677
PMCPMC11486229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.